Abcuro
Abcuro raises $200M Series C at $1.5B valuation
Quick Facts
Abcuro: Series C Funding Round
Abcuro has successfully raised $200M in Series C funding, reaching a valuation of $1.5B.
Company Overview
Antibody therapeutics for autoimmune diseases
Funding Details
The Series C round was led by RA Capital, with participation from Arch Venture Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Employees: 100+
- Category: HealthTech
Investment
Abcuro plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series C
- Arch Venture Partners: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
